Three endothelin family peptides (endothelin-1, -2 and -3) exert an extremely potent and long-lasting vasoconstrictor action as well as other various actions through stimulating two subtypes of receptor (ET A and ET B ). Vascular endothelial cells produce only endothelin-1. Although the pharmacological actions of exogenous endothelin-1 have been extensively analyzed, the physiological roles of endogenous endothelin-1 have long been obscure. Using potent and selective receptor antagonists, endothelin-1 has been demonstrated to contribute slightly to the maintenance of regional vascular tone. In gene-targeted mice, endothelin family peptides and their receptors have been shown to play an important role in the embryonic development of neural crest-derived tissues. In addition to its potent vasoconstrictor action, endothelin-1 has direct mitogenic actions on cardiovascular tissues, as well as co-mitogenic actions with a wide variety of growth factors and vasoactive substances. Endothelin-1 also promotes the synthesis and secretion of various substances including extracellular constituents. These effects of endogenous endothelin-1 would appear to be naturally concerned with the development and/or aggravation of chronic cardiovascular diseases, e.g. hypertension, pulmonary hypertension, vascular remodeling (restenosis, atherosclerosis), renal failure, and heart failure. A great many non-peptide and orally active endothelin receptor antagonists have been developed, and shown to exert excellent therapeutic effects in animal models as well as human patients with these diseases.
INTRODUCTION
Endothelin, a 21-amino-acid peptide, was initially identified as a potent vasoconstrictor substance isolated from the culture supernatant of porcine aortic endothelial cells. 1) This peptide, which was originally termed porcine endothelin and is now referred to as endothelin-1, has a molecular weight of 2492, free amino and carboxyl termini, and two intrachain disulfide bonds between residues Cys 1 -Cys 15 and Cys 3 -Cys 11 . Analysis of the human genome has revealed that two other endothelin isopeptides are encoded in separate genes, endothelin-2 and endothelin-3.
2) These isopeptides of endothelin show a high degree of primary amino acid sequence identity; all are 21-amino-acid polypeptides, containing two intrachain disulfide bonds, and all contain an identical hydrophobic C-terminal hexapeptide sequence. The three endothelin isopeptides exert their actions via stimulation of two subtypes of receptor, endothelin-A (ET A ) 3) and endothelin-B (ET B ), 4) which have been classified according to the relative binding affinities of the three isopeptides as follows; the order of affinity for the first receptor subtype, ET A , is endothelin-1, endothelin-2, endothelin-3, and the second receptor subtype, ET B , shows equipotent affinity for all three isopeptides. The presence of the three endothelin isopeptides and two receptor subtypes has been found in many mammalian species.
Vascular endothelial cells produce only endothelin-1. However, the genes encoding the three endothelin isopeptides are expressed with different patterns in a wide variety of cell types including vascular smooth muscle cells, cardiac myocytes, renal tubular epithelial cells, glomerular mesangial cells, bronchial epithelial cells, glial cells, pituitary cells, macrophages, and mast cells. The distribution of receptor subtypes also extends over the body, suggesting that these peptides may participate independently in complex regulatory mechanisms in various organs. In fact, in addition to causing vasoconstriction, endothelin isopeptides exert pleiotropic effects on non-vascular tissues, e.g., respiratory and gastrointestinal tract, kidney, endocrine glands, and central and peripheral nervous system 5) (Table 1) . Although a number of experimental results using exogenous endothelins have accumulated, it has been difficult to discuss the actual roles of endogenous endothelins. In parallel with the development of orally active non-peptide endothelin receptor antagonists as well as endothelin or its receptor gene-targeted mice, however, an array of evidence gradually accumulated to make persuasive explanation for the physiological and/or pathophysiological significance of endogenous endothelin. This review will focus on the plausible roles of endothelin-1 and the possibility of application of novel endothelin receptor antagonists as new therapeutic drugs.
PHYSIOLOGICAL SIGNIFICANCE OF ENDOGE-NOUS ENDOTHELIN
The pharmacological actions of exogenously applied endothelin have been extensively investigated. Endothelin-1 causes extremely potent and long-lasting vasoconstriction in most mammalian species including humans, both in vivo and in vitro. 5) The in vivo hemodynamic responses to intravenously injected endothelin-1 are complex, depending upon the vascular bed, and include both direct vasoconstrictor and indirect effects, e.g. endothelium (EDRF: endothelium-derived relaxing factor)-mediated vasodilatation, reflex-mediated responses, etc. For instance, endothelin-1 produces a significant decrease in cardiac output irrespective of possessing a direct positive inotropic action. 6) This might result from a decrease in venous return due to severe vasoconstriction of large veins and cardiac ischemia due to extreme coronary vasoconstriction.
Endothelin-1 exerts vasoconstrictor and vasodilator actions through stimulation of ET A receptors in vascular smooth muscle and ET B receptors in endothelial cells, respectively, in principle. However, ET B receptors also contribute to vasoconstriction in some blood vessels, e.g. mesenteric 7) and coronary 8) vasculature. Further, the relative importance of endothelin receptor subtypes in vascular tissues differs among species and among vascular beds even in the same animal. For example, the renal vasoconstriction by endothelin-1 is mediated by a mixed population of ET A and ET B receptors in rats 9) but mostly by ET A receptors in dogs 10) and humans. 11) Similarly, constrictions of pulmonary artery are mainly mediated by ET B receptors in rats 12) and rabbits, 13) whereas ET A receptors predominate in guinea-pig 14) and human 15) blood vessels. Further, although endothelin-1 shows extremely potent constrictive effects in airway smooth muscle, the receptor subtypes in the smooth muscle are complicated, and are not clear ET A and ET B subtypes. 16, 17) Thus, the summary in Table 1 represents only the general features of the actions and receptor subtypes of endothelins in various tissues.
Since endothelin-1 is endogenously synthesized and secreted in these tissues described in the table or in adjacent vascular endothelial cells or epithelial cells, it seems that endothelin-1 is a physiological regulator of vascular and/or other smooth muscle tonus. However, this is based only on indirect information, and it is essential to analyze the effects of potent and specific tools (receptor antagonists or biosynthesis inhibitors) and/or selective gene-targeting (of the peptide itself or receptors) before concluding that endothelin is actually playing such physiological roles.
2-1. Effects of Receptor Antagonists
An important milestone in the development of useful tools for the study of endothelins was the isolation of a cyclic pentapeptide, BE-18257B, from the fermentation products of Streptomyces misakiensis. 18) Modification of BE-18257B has led to identification of the cyclic pentapeptide BQ-123 19) and the linear tripeptide FR 139317, 20) both exhibiting higher affinity for the ET A receptor. Thereafter, many peptide antagonists have been developed, including TAK-044 with high antagonistic activity against both ET A and ET B receptors.
21) The first orally active nonpeptide antagonist was Ro 46-2005, with both ET A and ET B antagonistic activity. 22) Ro 46-2005 is a sulfonamide derivative, and subsequent structure-activity relationship analysis led to the discovery of Ro 47-0203, bosentan, a far more potent and relatively ET A receptor-selective antagonist. 23) One more important nonpeptide antagonist is SB 209670 with extremely high affinity for both ET A and ET B receptors, which was derived from another prototype structure, a diphenylindane compound. 24) There are now a large number of orally active nonpeptide antagonists exhibiting either ET A -or ET B -selective or ET A /ET B -nonselective activity, with the fundamental structure of either prototype compound, sulfonamide or diphenylindane (Table 2) .
In most species thus far examined, application of these endothelin receptor antagonists does not generally affect the basal blood pressure, leading the negative supposition that endothelin-1 may not play any significant physiological role in maintaining basal blood pressure. However, there are exceptional observations to this general supposition. For instance, intravenous infusion of TAK-044 in healthy men caused a moderate decrease in systemic blood pressure and a marked decrease in total peripheral resistance. 25) Infusion of BQ-123 into the brachial artery in humans also caused an increase in forearm blood flow. 26) In either anesthetized or conscious guinea-pigs, both BQ-123 and bosentan lowered blood 27) Further, removal of the vasodilator effect of nitric oxide (NO) by application of a NO-synthase inhibitor increased blood pressure in rats, which was reduced by either FR-139317 or bosentan. 28) Thus, the physiological role of endothelin-1 in maintaining basal blood pressure is still controversial, and further analysis with potent nonpeptide receptor antagonists would be helpful to clarify this issue. Also, the other potential physiological roles of endogenous endothelins in individual organs need to be clarified in future.
2-2. Analysis of Gene-Targeted Mice The production of endothelin-deficient and endothelin receptor-deficient mice by means of gene targeting has shown that the endothelins have crucial roles in normal embryonic development. Endothelin-1-deficient mice have craniofacial and cardiac abnormalities and die of respiratory failure soon after birth. 29) In contrast, ET B -deficient mice exhibit aganlionic megacolon associated with coat color spotting, resembling a hereditary syndrome of humans, Hirschsprung's disease. 30, 31) Surprisingly, targeted disruption of endothelin-3 resulted in the development of an identical syndrome, suggesting that interaction of endothelin-3 and the ET B receptor is essential for the development of enteric neurons and epidermal melanocytes. 32) Furthermore, ET A receptor-deficient mice exhibit the same craniofacial and cardiac defects as endothelin-1-deficient mice, again suggesting that interaction of endothelin-1 and the ET A receptor is essential for the embryonic development of cranial neural crest-derived tissues.
33) It has recently been shown that, in endothelin converting enzyme-1 (ECE-1) knockout mice, the absence of ECE-1 has a similar effect on development to that of the combined knockout of endothelin-1 and endothelin-3. 34, 35) Thus, the endothelin system is essential for some part of embryonic development, and the precise physiological roles of endothelins in developmental biology are now under investigation. 36, 37) Since the complete disruption of either endothelin or its receptor by gene targeting (homozygous, Ϫ/Ϫ) is lethal, mice with partial disruption (heterozygous, ϩ/Ϫ) have been used for further analysis. Endothelin-1 ϩ/Ϫ heterozygous mice appear morphologically normal and are fertile, and their plasma and tissue endothelin-1 levels are about half of those in wild-type mice. The endothelin-1 ϩ/Ϫ heterozygous mice exhibit slight hypertension by about 10 mmHg compared with wild-type litter mates. 29) This phenomenon might naturally be interpreted to indicate that endothelin-1 may stimulate ET B receptors on vascular endothelial cells in normal conditions and release EDRF, thereby causing vasodilatation, and if such an ET B receptor-stimulating effect of endothelin-1 is decreased, the blood pressure would increase due to the diminution of vasodilatation. This interpretation seems to be likely, since the normal plasma concentration of endothelin-1 is usually around or slightly below the threshold concentration for stimulating the ET B receptor. Supporting evidence comes from observations that ET B receptor ϩ/Ϫ heterozygous mice also exhibit slight hypertension. 38) In addition, precise physiological examination has revealed that the mean arterial pressure and renal nerve activity relationship is reset upward in endothelin-1 ϩ/Ϫ heterozygous mice, with significant impairment of CO 2 (chemoreceptor)-mediated reflex control of sympathetic nervous activity. 39, 40) Thus, endothelin-1 can be thought to participate in the central reflex control of blood pressure. Taken together, endogenous endothelin-1 appears to play physiological roles in the control of basic blood pressure via central and peripheral mechanisms.
The deoxycorticosterone acetate (DOCA)-salt-induced hypertension in adult ET B receptor-deficient rats, which is usually a lethal phenotype but is "rescued" by transient and local re-expression of the ET B receptor, was shown to be salt-sensitive and exhibit severe renal vasoconstriction mediated by the ET A receptor 41) as well as renal damage. 42) These results strongly suggest that the ET B receptor mediates a physiologically relevant natriuretic and vaso-protective effects in the kidney. Further studies are needed to clarify the actual physiological roles of endogenous endothelins to maintain cardiovascular homeostasis.
PATHOPHYSIOLOGICAL SIGNIFICANCE OF EN-DOGENOUS ENDOTHELIN
At the time of discovery of endothelin-1, because of its potent and long-lasting vasoconstrictor effects, the first clinical syndrome in which this peptide was postulated to be pathologically relevant was hypertension. At the 2nd International Conference on Endothelin, an extraordinary finding concerning endothelin-secreting tumors was reported. 43) There was a good correlation between the plasma level of endothelin-1 and elevated blood pressure in two patients with hemangioendothelioma, a rare form of malignant tumor of endothelial cells. In these two patients, the elevated plasma levels of endothelin-1 and hypertension returned to normal following surgical removal of the tumor, and both parameters rose again along with the recurrence of tumor in one of the patients. Another impressive finding was that phosphoramidon, which exhibits an ECE-inhibiting action, lowered blood pressure in spontaneously hypertensive rats but not in normotensive rats. 44) These findings naturally lead to the speculation that endothelin-1 might be involved in the pathogenesis of hypertension. Recent studies have provided convincing evidence to indicate that endothelin-1 actually plays pathophysiological roles in a number of not only cardiovascular but also noncardiovascular diseases. 45) 3-1. Hypertension There are currently many reports regarding the plasma levels of immunoreactive endothelin-1, and the results concerning the relationship between the plasma level and severity of hypertension are fairly conflicting. 46) In spontaneously hypertensive rats (SHR), BQ-123 was efficacious in some studies but not in the others. 47, 48) These divergent observations have gradually given rise to the negative supposition that endothelin-1 may not play any significant pathophysiological role in the development of hypertension. Nevertheless, there have been many reports suggesting that endothelin-1 may be deeply concerned with the etiology or aggravation of various kinds of hypertension.
In DOCA-salt-induced hypertensive rats 49) and hyperinsulinemic hypertensive rats, 50) the concentration of immunoreactive endothelin-1 in vascular tissue was significantly correlated with the level of systemic blood pressure, even if no appreciable change in plasma level of endothelin-1 was detected. The elevated blood pressure was markedly reduced by BQ-123, 51) FR-139317 52) or bosentan 53) in DOCA-salt-induced hypertensive rats and by bosentan in hyperinsulinemic hypertensive rats. 50) Although the effects of peptide antago-nists in SHR are currently controversial, 47, 48) a nonpeptide antagonist, SB209670, has been shown to exert significant and long-lasting hypotensive actions in SHR. 24) The non-peptide antagonists have been demonstrated to lower blood pressure in various animal models of hypertension; e.g., sodium depletion-induced hypertension in squirrel monkey, 22) renal hypertension in dogs 54) and mouse renin transgenic ((mRen-2)27) hypertensive rats. 55) In ((mRen-2)27) hypertensive rats, in which the fulminant hypertension is assumed to be due to overproduction of angiotensin II, SB209670 infusion caused a sustained decrease in systemic blood pressure, the degree of which was identical to that caused by losartan, an angiotensin II receptor antagonist. The combined use of SB209670 and losartan produced a far greater decrease in blood pressure in an additive fashion, suggesting that accumulated endothelin-1, the overproduction of which might be induced by angiotensin II, may also be concerned with this hypertension. From these results, although the involvement of endogenous endothelin-1 in mild to moderate hypertension remains controversial, it is strongly suggested that endothelin-1 may be implicated in certain types of hypertension in humans, particularly in fulminant forms or stages of the disease.
3-2. Pulmonary Hypertension and Lung Diseases
Pulmonary hypertension (PH) has been shown to be associated with increased production of endothelin-1 in various animal models as well as human patients. The plasma concentration of endothelin-1 clearly correlated with the severity of disease. [56] [57] [58] In rats with idiopathic pulmonary hypertension (IPH), an increase in endothelin-1 mRNA expression has been detected. 59) It was also found that cultured smooth muscle cells isolated from the pulmonary artery of rats with IPH not only overexpressed endothelin-1 mRNA but also produced more endothelin-1 peptide compared with cells from normotensive rats. 60) In young patients with pulmonary hypertension secondary to congenital heart disease, the elevated plasma level of endothelin-1 dramatically decreased following successful surgical repair. 61) Furthermore, in patients with pulmonary hypertension of various origins (pulmonary arteriopathy, reactive pulmonary hypertension due to heart failure, plexogenic pulmonary arteriopathy, and cryptogenic fibrosing alveolitis), a marked increase in expression of endothelin-1-like immunoreactivity has been demonstrated in vascular endothelial cells in lung tissue. 62, 63) These findings suggest that local production of endothelin-1 may contribute to the pulmonary vascular abnormalities associated with PH.
When rats are exposed to chronic hypoxia, pulmonary hypertension develops (HPH: hypoxic pulmonary hypertension), with a high plasma level of endothelin associated with increased mRNA levels for endothelin-1, and ET A and ET B receptors in the lung tissue. 64) Chronic treatment of HPH rats with either BQ-123, 65) bosentan, 66) A-127722, 67) CI-1020 68) or SB217142 69) significantly attenuated the development of pulmonary hypertension and pulmonary arterial wall thickening, and reduced the degree of right ventricular hypertrophy. In rats with monocrotaline-induced pulmonary hypertension (MPH), plasma endothelin-1 levels increased progressively, and preceding the development of pulmonary hypertension. 70) Infusion of BQ-123 reduced the progression of the disease and right ventricular hypertrophy and prevented the characteristic thickening of the pulmonary arterial media.
It has also been demonstrated that MPH was significantly inhibited by endothelin receptor antagonists, FR-139317 (dog), 71) bosentan (rat), 72) and LU135252 (rat), 73) and also by an ECE inhibitor, FR-901533 (rat). 74) In contrast to other animal models of pulmonary hypertension, MPH is associated with decreased synthesis of endothelin-1 in the lungs, despite a marked increase in its plasma level. This may be related to the increased synthesis of endothelin-1 in the heart and kidney, and a possible concomitant loss of pulmonary clearance of this peptide. MPH is usually associated with severe inflammatory responses in the lung (e.g., edema) and tissue remodeling. The powerful proinflammatory 75, 76) as well as collagen synthesis-stimulatory 77) actions of endothelin-1 might also be exerted in this disease. In chronic heart failure rats (permanent coronary artery ligation) with severe PH, continuous infusion of BQ-123 significantly reduced both right ventricular systolic pressure and central venous pressure. 78) The endothelin receptor antagonists thus far investigated are remarkably efficacious in most animal models of pulmonary hypertension, e.g. premature lambs with hyaline membrane disease, 79) pigs with HPH, 80) sheep with endotoxin-induced PH, 81) and lams with PH induced by aortic and pulmonary arterial shunt. 82) In a multi-center, double-blind, placebo-controlled trial in 48 patients with chronic heart failure treated with an angiotensin converting enzyme (ACE) inhibitor and diuretics, acute ET A receptor blockade by sitaxsentan (TBC 11251) produced selective pulmonary vasodilation associated with a reduction in plasma endothelin-1 83) (Fig. 1) . Endothelin-1 has been shown to exert an extremely potent contractile action on isolated tracheal and bronchial smooth muscle. 84, 85) The endothelin-1 content of broncho-alveolar lavage fluid was increased several-fold in asthmatic patients 86, 87) and the plasma level of endothelin-1 was also increased in such patients. 88) Bronchial epithelial cells obtained from asthmatics expressed endothelin-1 mRNA and released significant quantities of endothelin-1 into the culture medium, whereas those from normal humans did not. 89) These findings remain as circumstantial evidence suggesting that endothelin-1 may be a potential mediator of asthmatic disease. In this connection, two studies are noteworthy. In allergic sheep, BQ-123 given either intravenously or by aerosol inhibited antigen inhalation-induced bronchoconstriction by approximately 50% in the late (5-6 h) stage, with no appreciable effects on the immediate response after antigen challenge. 90) It was also shown in a sheep model that endothelin-1 applied by aerosol produced airway hyperresponsiveness and that BQ-123 blocked the airway hyper-response to carbachol only in the late stage (24 h) after sensitization. Similarly, in guinea-pigs sensitized and challenged with ovalbumin, BQ-123 inhibited the late airway response without affecting the immediate response following immune challenge.
91) It is of particular interest that an ET B receptor antagonist, BQ-788, selectively inhibited the immediate response by 60% in this guinea-pig model.
Since asthmatic responses in animal models are derived mostly from immunological reactions, and endothelin-1 itself causes long-lasting bronchial sensitization, 92) it can be speculated that endothelin-1 is involved in this disease as a proinflammatory factor as well as a bronchoconstrictive factor. In fact, endothelin-1 has been shown to increase the expression of adhesion molecules (ICAM-1, VCAM-1, E-selectin) 93) and to promote adhesion of neutrophils to endothelial cells. 94) Further, endothelin-1 increases the production of superoxide by human 95) and guinea-pig 96) macrophages, and induces release of a number of cytokines from human peripheral monocytes, including TNF-a (tumor necrotic factor a), GM-CSF (granulocyte macrophage-colony stimulating factor), IL-1 (interleukin-1), IL-6, IL-8 and MCP-1 (monocyte chemotactic protein-1). [97] [98] [99] The localized distribution of endothelin-1 in airway epithelial and vascular endothelial cells in the bronchial tissue and the specific increase in endothelin-1 immunoreactivity in these cells in asthmatics 100) may be an important clue to solve the complicated problems underlying this disease.
3-3. Renal Failure Accumulating evidence suggests that endothelin-1 is possibly involved in the pathogenesis of acute renal failure (ARF). For example, the plasma concentration of endothelin-1 in patients with ARF was increased, 101) and in animal models, the tissue level of endothelin-1 in the post-ischemic kidney was elevated 102) and endothelin-1 and -3 binding affinity at the renal ET A and ET B receptors during reperfusion after ischemia was increased time-dependently. 103) Administration of an antibody to endothelin-1 before renal artery clamping in rats prevented the increase in periglomerular arteriolar resistance, the reduction in single nephron glomerular filtration rate, 104) and the histological changes that accompany proximal renal tubular necrosis. 105) Studies with endothelin receptor antagonists provide more persuasive evidence that endothelin-1 may play a pathogenic role in the development and/or maintenance of ARF. BQ-123 was first shown to attenuate the renal functional impairment, tubular degenerative changes, and mitochondrial calcium accumulation following bilateral renal artery occlusion in rats 106) and aortic cross-clamping in dogs. 107) Thereafter, it was shown that ischemia/reperfusion-induced renal dysfunction and histological damage in rats were effectively attenuated by orally active non-peptide endothelin receptor antagonists, SB209670, 108) LU135252 109) and ABT-627. 110) Furthermore, non-peptide antagonists were demonstrated to be effective in dogs with ARF induced by ischemia 111, 112) or endotoxin, 113) and in rats with ARF induced by radiocontrast 114) or glycerol. 115) An ECE inhibitor was also effective in inhibiting ischemia-induced ARF. Initially, a nonspecific metalloproteinase inhibitor, phosphoramidon, was utilized, and was shown to attenuate ischemia-ARF-associated renal damage in rats. 116) Recently, a selective and potent ECE inhibitor, SM-19712, was shown to exert excellent protective effects on AFR-associated functional and tissue damage in the kidney of rats 117) (Fig. 2) . These results strongly suggest that overproduction of endothelin-1 plays an important patho-physiological role in the development of ARF of various origin.
The potent immunosuppressive agent, cyclosporin, has been extensively used primarily to prevent allograft rejection and for a number of other diseases mediated by immunological mechanisms. Nephrotoxicity is one of the major side effects of cyclosporin and is characterized by renal vasoconstriction with peritubular capillary congestion and tubular toxicity.
118) It has been demonstrated that cyclosporin causes an increase in plasma endothelin-1 level, 119, 120) renal endothelin receptor density and urinary endothelin excretion. 121, 122) Further, both an endothelin receptor antagonist (BQ-123, PED-3512) and anti-endothelin antiserum were effective in preventing the renal hemodynamic alterations induced by systemic administration of cyclosporin in rats. 123, 124) All these observations favor the view that cyclosporin may cause renal toxicity via increasing renal endothelin-1 production. Recently, another potent immuno-suppressive agent, FK506, was also shown to cause renal damage in rats. 125) This renal dysfunction was also prevented by an endothelin receptor antagonist. Interestingly, an endothelin receptor antagonist markedly increased the viability of transplanted liver graft in pigs. 126) BQ-123 infused 24 h after the onset of ischemia was shown to effectively reverse renal damage in rats with ARF, indicating that ET A receptor antagonists are efficacious even in the treatment of established renal failure. 127) Since the detrimental action of endothelin-1 on renal function in ARF is more marked during the maintenance phase than the initial phase after ischemia, endothelin receptor antagonists are thought to be more effective in reversing than in preventing renal impairment. In fact, endothelin receptor antagonists (BQ-123, SB 209670) improved the survival rate of rats, and surviving animals exhibited a significant increase in glomelular filtration rate, decrease in plasma creatinine, and improvement in tubular function. 128, 129) In rats with chronic renal failure (CRF) exhibiting marked proteinuria, decreased creatinine clearance, high blood pressure, and decreased renal function 8 weeks after 5/6 nephrectomy, cortical expression of mRNA of prepro-endothelin-1 and ET A receptor increased, but that of ET B receptor decreased. Admin-istration (1-3 mg/d) of S-0139, an ET A receptor-specific antagonist, significantly improved all the symptoms. 130) Further, 3 weeks of treatment with another ET A receptor-specific antagonist, LU135252, effectively prevented the aggravation of hypertension and vascular hypertrophy as well as the progression of renal insufficiency in rats with CRF subjected to surgical renal mass 5/6 ablation. 131) In these rats, a positive correlation was found between plasma, aortic and mesenteric arterial endothelin-1 levels and systolic blood pressure, as well as blood vessel hypertrophy. Myocardial capillary supply, which is particularly important for tolerance of ischemia in CRF, seems to be modulated and regulated predominantly by endothelin-1, since the decrease in capillary supply in experimental CRF was effectively prevented by an ET A receptor antagonist but not by an ACE inhibitor. 132) These results strongly suggest that enhanced endothelin-1 production in renal tissues plays an important pathophysiological role in CRF.
3-4. Vascular Remodeling
In addition to acute vasoconstrictor effects, endothelin-1 exerts chronic actions on vascular tissues and appears to be deeply implicated in the proliferative responses associated with vascular diseases. 133, 134) Endothelin-1 has been shown to stimulate the expression of c-fos, c-jun, c-myc 135) increase the incorporation of [ 3 H]-thymidine into DNA and cause proliferation of vascular smooth muscle cells 136) and fibroblasts. 137) Endothelin-1 as well as angiotensin II acts as progression but not competence growth factor in vascular smooth muscle cells. 138) Endothelin-1 has also been shown to induce the expression of mRNA encoding platelet-derived growth factor (PDGF) and transactivating growth factor-b (TGF-b). 139) In addition to its direct mitogenic action, a synergistic action exists between endothelin-1 and a wide variety of growth factors, including PDGF, basic fibroblast growth factor (bFGF), endothelial growth factor (EGF), insulin and angiotensin II, suggesting that endothelin-1 may also function as a co-mitogen. 134, [140] [141] [142] An additional important role of endothelin-1 in the pathophysiology of vascular disease is promotion of the synthesis and secretion of glycoproteins, thrombospondin, fibronectin and tenascin, thereby leading to the modification of extracellular constituents in cardiovascular tissues. 143) Immediately after injury of arteries, platelets accumulate at the site of injury and, on activation by thrombin, release a number of substances, including serotonin and PDGF. 144) Then, medial smooth muscle cells shift from a contractile to a synthetic phenotype, migrate, proliferate, and produce extracellular matrix, thereby resulting in restenosis. 145) Cultured vascular smooth muscle cells explanted from human coronary artery secrete a considerable amount of endothelin-1 and big endothelin-1. 146, 147) In balloon angioplasty-induced neotintima in rat carotid artery, the mRNAs expression of endothelin-1, endothelin-3, ECE-1, ET A and ET B receptors was increased, and SB209670 strongly attenuated the neointimal formation. 134) In a restenosis model of porcine carotid artery, it has also been shown that the number of endothelin receptors is increased. 148) ABT147627, an ET A receptor-selective antagonist, significantly reduced neointimal hyperplasia in porcine coronary stented injury. 149) These results strongly suggest that endothelin-1 may be involved in the development of restenosis following vascular angioplasty.
Plasma endothelin-1 level increased in parallel with the number of vascular beds involved with atherosclerotic disease in the aortic, coronary, renal and carotid vascular beds. 150) Positive staining of endothelin-1-like immunoreactivity was observed in endothelial and medial smooth muscle cells in atherosclerotic aorta. Radioactive endothelin-1 accumulated within the atherosclerotic plaques of hypercholesterolemic rabbits following systemic administration of 125 Iendothelin-1.
151) Enhanced endothelin-1 binding was also detected in hyperplastic lesions induced in porcine coronary arteries and in atheromatous lesions of human coronary arteries and saphenous veins. 152, 153) In stable angina pectoris pa- tients, the blood endothelin-1 level immediately downstream from the atherosclerotic plaque significantly increased following percutaneous transluminal coronary angioplasty. 154) Oxidized low-density lipoprotein (LDL), a well-known atherogenic risk factor, has been shown to induce mRNA expression and the release of endothelin-1 from human and porcine macrophage and endothelial cell cultures 155, 156) and the proliferation of vascular smooth muscle cells via ET A receptor stimulation. 157) In addition, the increased release of endothelin-1 stimulates the synthesis of FGF-2 158) and epiregulin, 159) a potent smooth muscle cell-derived mitogen, as well as TGF-b and PDGF. 139) Endothelin-1 also increases neutrophil 160) and platelet 161) adhesion, thereby promoting lesion growth and coronary thrombosis. These results suggest that endothelin-1 is deeply concerned with the pathophysiology of atherosclerosis. In fact, chronic ET A receptor blockade with LU135252 for 30 weeks restored nitric oxide-mediated endothelial function and significantly inhibited atherosclerosis in apolipoprotein E (apoE)-deficient mice, 162) a mouse model of human atherosclerosis (Fig. 3) . In human atherosclerotic lesions 163) and apoE-deficient mice, 164) an increase in ET B receptor density was observed, particularly in foamy macrophages and T lymphocytes in fatty streaks and fibrous plaques, suggesting that the ET B receptor is also involved in the progression of atherosclerosis. In LDL receptor-deficient mice, chronic treatment with LU224332 (a mixed ET A and ET B receptor antagonist) for 8 weeks markedly reduced the development of atherosclerosis. 165) It has also been demonstrated in experimental porcine hypercholesterolemia that coronary endothelial function was markedly preserved by chronic treatment (12 weeks) with either an ET A receptor specific antagonist (ABT-627) 166) or a combined ET A /ET B receptor antagonist (RO 48-5695). 167) Recently, peroxisome proliferator-activated receptor (PPAR) activators have been shown to inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway, 168) suggesting a novel role for PPAR in vascular endothelial function in atherosclerosis as well as hyperinsulinemia. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to preserve endothelial function through inhibiting prepro endothelin-1 mRNA expression.
169)
3-5. Chronic Heart Failure In chronic heart failure (CHF), as myocardial performance deteriorates, systemic neurohumoral reflexes become operative to maintain cardiac output, organ perfusion and circulatory homeostasis. The renin-angiotensin axis, vasopressin and the sympathetic nervous system are activated. Although these reflexes are all adaptive responses, they may result in the augmentation of peripheral vascular tone, which is deleterious to the failing heart because it markedly increases afterload. These neurohumoral factors are also known to enhance endothelin-1 production in endothelial cells. 170) In patients with CHF, left 171) and right ventricular 172) tissue concentrations of endothelin-1 as well as ECE-1 activity, 173, 174) and the plasma concentrations of both endothelin-1 175, 176) and its precursor big endothelin-1 are increased. Plasma concentrations of both peptides are positively correlated with the severity of heart failure and are of prognostic value. [175] [176] [177] The density of ET A receptors is also increased in the heart of CHF patients. 171, 178) Acute intravenous infusion of an ET A /ET B receptor antagonist, bosentan, in CHF patients produced changes in hemodynamic parameters, with reductions in mean arterial, pulmonary arterial, right atrial and pulmonary artery wedge pressure, decreases in systemic and pulmonary vascular resistance, and a resultant increase in stroke volume and cardiac output. 179, 180) Either an ECE inhibitor 181) or ET A receptor antagonist 182, 183) caused vasodilation in CHF patients already receiving treatment with an angiotensin-converting enzyme inhibitor. These findings clearly indicate that endothelin-1 contributes to the maintenance of vascular tone in such patients. In rats with myocardial heart failure, the surviving myocardium expressed a great amount of endothelin-1 as well as ET A receptors, 184, 185) suggesting that endogenous endothelin-1 might help to support cardiac function through the up-regulation of the endothelin system. 186) Up-regulation of the endothelin pathway may be beneficial in providing short-term inotropic support for the failing my- ocardium in which b-adrenergic responsiveness is frequently attenuated. However, prolonged stimulation by up-regulated endothelin pathways may have important maladaptive effects on myocardial structure and function, thereby leading to fatal events, i.e., CHF. In fact, rats that survived for more than 10 d after left coronary artery ligation gradually died of severe CHF in parallel with the increase in endothelin-1 production and up-regulation of ET A receptors in the heart. Long-term treatment with an ET A receptor antagonist, BQ-123, by means of a subcutaneous osmotic mini-pump not only greatly improved the survival rate of rats but also ameliorated left ventricular dysfunction and prevented harmful ventricular remodeling 187) (Fig. 4) . Likewise, the effectiveness of chronic treatment with orally active ET A or ET A /ET B receptor antagonists has been demonstrated in animal models of CHF due to myocardial infarction (rat), [188] [189] [190] [191] [192] cardiomyopathy (hamster), 193, 194) rapid ventricular pacing (dog [195] [196] [197] [198] [199] and pig 200, 201) ), renal hypertension (rat) 202, 203) and coronary microembolism (dogs). 204) In patients with acute myocardial infarction, which often leads to CHF, the plasma level of endothelin-1 seems to be an indicator of long-term prognosis; the higher the plasma level of endothelin-1, the higher the long-term mortality. [175] [176] [177] 205) Thus, endothelin-1 appears to cause progressive aggravation of the failing myocardium.
Short-term oral administration of an ET A /ET B receptor antagonist (bosentan) 180) or an ET A receptor antagonist (BQ-123, 181) LU135252, 182) sitaxsentan (TBC 11251) 83) ) to patients with CHF irrespective of conventional therapeutic treatment improved hemodynamic function, which indicates the therapeutic potential of endothelin receptor antagonists in the management of CHF. Chronic (2-week) bosentan treatment improved hemodynamic parameters in a preliminary clinical trial for CHF patients. 180) Nevertheless, studies with long-term administration of endothelin receptor antagonists in CHF patients are still required to determine whether they can halt or reverse the progression of structural alterations of the myocardium, improve survival and offer additional therapeutic benefit to currently used drug treatment regimens.
Further, it is still obscure which type of receptor antagonist, ET A or ET B , is more beneficial for the long-term treatment of CHF. Local infusion of an ET A receptor antagonist (BQ-123) into the non-dominant brachial artery showed vasodilating effects in CHF patients, while infusion of an ET B receptor antagonist (BQ-788) caused vasoconstriction, suggesting that ET B receptor antagonism appears to be deleterious in CHF. 183) In dogs with CHF induced by rapid right ventricular pacing, unexpectedly however, long-term oral administration of an ET B receptor antagonist (K-8794) effectively prevented body fluid retention through the suppression of activation of the renin-angiotensin-aldosterone system. 206) This effect appears to be more beneficial for the treatment of CHF than the hemodynamic disadvantages caused by ET B receptor antagonists, e.g. increase in mean arterial pressure and systemic vascular resistance. Thus, further studies are needed to determine which receptor type antagonist is more suitable.
In addition to the chronic cardiovascular diseases described here, the endothelin system is also involved in the development or progression of certain disease in which endothelin-1 level and/or endothelin receptor density are increased in experimental conditions. The rationale that endothelin receptor antagonists have therapeutic potential appears to be quite strong in gastric mucosal injury, 207) cerebral vasospasm following subarachnoid hemorrhage, 208, 209) and prostate cancer. 210, 211) 4. CONCLUSION Since the discovery of endothelin in 1988, extensive investigations have been carried out, and as a result, its basic pharmacological and biochemical properties have mostly been characterized, including its biosynthesis, receptors, gene expression, endothelin converting enzyme and intracellular signal transduction pathways following receptor stimulation. The production of gene-targeted mice revealed that endothelins have crucial roles in normal embryonic development, the endothelin-1 and ET A receptor system being dispensable in craniofacial and cardiac development, whereas endothelin-3 and the ET B receptor system are essential for the development of enteric neurons and epidermal melanocytes. In addition to acute effects, e.g. vascular and other smooth musclecontracting and hormone-releasing actions, etc., endothelin-1 has potent mitogenic properties and causes proliferation and hypertrophy of a number of cell types, including vascular smooth muscle cells, cardiac myocytes, mesangial cells, bronchial smooth muscle cells and fibroblasts. Endothelin-1 also induces the expression of several protooncogenes (c-fos, c-jun, c-myc, etc.) as well as growth factors, vasoactive substances, and extracellular constituents. These pleiotropic actions of endothelin-1 are considered to be deeply concerned with cellular and tissue remodeling, and to be responsible for pathophysiological conditions associated with long-term changes in chronic cardiovascular diseases. Late in the 20th century, in addition to peptide endothelin receptor antagonists, a wide variety of orally active non-peptide receptor antagonists with extremely potent and selective activity were developed. In animal models of various chronic cardiovascular diseases (hypertension, pulmonary hypertension, renal failure, vascular remodeling, heart failure, etc.), these receptor antagonists have been shown to exhibit desirable preven- tive and/or curative effects, suggesting that they are of potential therapeutic value, and some of them are already under clinical investigation.
